Comparative Pharmacology
Head-to-head clinical analysis: LOXAPINE SUCCINATE versus LOXITANE IM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXAPINE SUCCINATE versus LOXITANE IM.
LOXAPINE SUCCINATE vs LOXITANE IM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine is a dibenzoxazepine antipsychotic that exerts its effects primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors. It also has moderate affinity for histamine H1, alpha-1 adrenergic, and muscarinic acetylcholine receptors.
LOXITANE IM (loxapine) is a dibenzoxazepine antipsychotic. Its mechanism of action is not fully established but is thought to be mediated via antagonism of central dopamine D2 and serotonin 5-HT2A receptors. It has high affinity for D2, D3, D4, and 5-HT2A receptors and low affinity for D1 receptors. It also has moderate affinity for histamine H1 and alpha1-adrenergic receptors.
Initial: 10 mg twice daily orally; increase to 25-50 mg twice daily over 7-10 days; maximum 250 mg/day. IM: 12.5-50 mg every 4-6 hours.
Adults: 12.5-50 mg IM every 4-6 hours as needed, not to exceed 150 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12–19 hours (mean 16 hours) after oral administration; steady-state reached within 3–5 days.
Terminal elimination half-life: 8-12 hours. Clinically, steady-state reached in 2-3 days; dosing interval based on q6-12h.
Renal (approximately 60% as metabolites, <1% unchanged) and fecal (approximately 40% as metabolites).
Primarily renal: 70% as metabolites; biliary/fecal: 30% as metabolites and unchanged drug.
Category C
Category C
Antipsychotic
Antipsychotic